Take a look at our recent team-building activity – the egg drop challenge! The goal of the challenge is to build a contraption to keep an egg safe while it falls. Using supplies from around the office, ONO teams worked together to design and build a container that protected their egg from a 10-foot drop. Why did we spend our time doing something like this? Because building a team that’s willing to come together and explore is part of sparking innovation. And innovation is key to ONO’s mission. A big congrats to the winning teams that were able to keep their egg intact. Keep innovating! #ONOPHARMAUSA
ONO PHARMA USA
Pharmaceutical Manufacturing
Cambridge, Massachusetts 12,792 followers
Identifying and developing innovative and breakthrough oncology, immunology, neurology and specialty pharma products
About us
ONO PHARMA USA is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717, with headquarters in Osaka, Japan. For over 300 years, ONO has been committed to delivering novel medicines to patients with high unmet medical need. Our passion has led to first-in-class therapies including the world’s first chemically synthesized prostaglandins as well as nivolumab, the world’s first anti-PD-1 antibody. These drugs have changed the treatment paradigm and outlook for millions of people globally. Today, ONO has a growing pipeline of innovative therapeutics across four focus areas: oncology, immunology, neurology, and specialty medicine. ONO is committed to Challenging the Unknown, relentlessly pursuing research that will bring safe and effective solutions to more patients around the world. For information on our community guidelines, visit: http://bit.ly/43MdR0S
- Website
-
https://us.ono-pharma.com/
External link for ONO PHARMA USA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
Locations
-
Primary
1 Main Street
Suite 1050
Cambridge, Massachusetts 02142, US
Employees at ONO PHARMA USA
Updates
-
Today our parent company Ono Pharmaceutical Co. Ltd. announced the completion of its acquisition of Deciphera Pharmaceuticals, Inc. To learn more, please see the press release: https://lnkd.in/gqRUV2MM
-
ONO is proud to provide support for ALL our patients. We are united in the mission to develop treatments that bring hope, without discrimination. #PrideMonth #ONOPHARMAUSA
-
-
We were thrilled to welcome a special visitor to ONO PHARMA USA recently! Toichi Takino, Ph.D., Representative Director, President and COO of ONO Pharmaceutical in Japan, was in town and came by our Cambridge office to talk about his career path at ONO with U.S. employees. We enjoyed the time we got to spend with Mr. Takino, discussing ONO’s mission and the great things that are in store. Looking forward to the next trip!
-
-
The past four days a team from ONO has been in Chicago for the ASCO annual meeting. In addition to answering questions from HCPs about our ongoing clinical programs and providing PCNSL disease awareness, we’ve been hearing from medical experts about the latest innovative treatment options in the oncology space. We revealed a new, larger ONO booth that showcased our robust pipeline and commitment to developing new therapies that may shape the futures for those fighting rare forms of cancer, like PCNSL. As we head back to Cambridge, we are feeling energized and our commitment to bringing new treatment options to patients is stronger than ever. #ONOPHARMAUSA
-
-
ONO PHARMA USA welcomes visitors with a new look! When visitors come to see our offices in Cambridge, they will now be greeted with new signage and a bright reception desk set against beautiful views of the Boston skyline. First impressions matter and this refresh of our office entrance is just one of the many ways we are building our presence in Cambridge. Archana (Arch) Sondhi David Trexler #ONOPHARMAUSA
-
-
Our new website wins gold! We are very proud to announce that our website has been recognized by The Stevie Awards in the Gold category. This Stevie Award is a leading business award that recognizes the achievements and positive contributions of organizations worldwide. Why is this such a win for ONO? Our work is rooted in our passion for transforming the lives of patients, and our new website allows us to effectively share this mission and the impact that we are making. Needless to say, we are extremely honored to have this work recognized as a Gold Stevie Award winner. Check out our new, award-winning website here: https://us.ono-pharma.com/ #ONOPHARMAUSA
ONO Pharma USA
us.ono-pharma.com
-
About 40 miles from Boston, you’ll find a tranquil respite for people living with cancer. Situated on eight acres, the Virginia Thurston Healing Garden Cancer Support Center offers support and peace to those impacted by cancer. Its offerings complement a patient’s medical care with educational programs, stress-reducing activities, and services designed to promote resilience and recovery. Employees from ONO PHARMA USA recently visited the Healing Garden Community to clean up the gardens for spring and plant flowers in pots painted with Japanese characters that symbolize healing and renewal. Our goal is to help the center maintain its space for those living with the realities of cancer. This was a great opportunity for our team to come together and make a small difference in the lives of patients and their families. #ONOPHARMAUSA
-
-
This month, we honor our Asian American and Pacific Islander (AAPI) employees' contributions to ONO's culture. As a Japanese company, our connection to Asian heritage runs deep – all the way back to the founding of ONO PHARMA in 1717 in Osaka. Our rich history continues to shape who we are and the way we work. Diversity is part of our culture. We believe different ideas and perspectives help us find new, innovative ways to bring hope to patients around the world. #AAPIHeritageMonth #ONOPHARMAUSA
-
-
Nearly 25,000 people will be diagnosed with brain tumors this year. In honor of Brain Tumor Awareness Month, we’re shining a light on a family impacted by such a diagnosis. In 2019, Brandon Cormier’s world changed forever when his father was diagnosed with Primary Central Nervous System Lymphoma (PCNSL), a CNS lymphoma that is most often discovered as a tumor in the brain. The Cormier family’s experience learning about these types of tumors was challenging, mostly because of the lack of online information about the disease, limited clinical trials researching it, and few potential treatments. ONO is committed to helping families like the Cormiers. We are conducting a research study, the PROSPECT Study, for people with PCNSL: https://lnkd.in/gMvzQveC. We're grateful Brandon visited ONO’s Cambridge office to share his family's story with our team. Learning how his family managed his father’s PCNSL diagnosis was an inspiring reminder that the work we are doing now may someday bring new treatment options to patients who need them. #BrainTumorAwarenessMonth #ONOPHARMAUSA
-